Mirum Pharmaceuticals' Ctexli wins FDA approval for CTX, a rare lipid storage disease. The company projects 2025 global sales of $420–$435 million.

Today, the U.S. Food and Drug Administration approved Ctexli (chenodiol) for the treatment of cerebrotendinous xanthomatosis (CTX) in adults. Ctexli is the first FDA-approved drug to treat CTX, a very ...

Preeclampsia, a complication of pregnancy characterized by high blood pressure and high levels of protein in the urine ...

The following is a summary of “Causal inference study of plasma proteins and blood metabolites mediating the effect of ...

Alzheimer’s Disease (AD) is a major neurodegenerative disorder contributing to 60-70% of dementia cases globally, affecting approximately 50 million ...

Researchers have discovered that naturally occurring gut microbes produce indoles—compounds that play a key role in ...

The bill bars measured marijuana metabolites in a person’s urine, blood serum, or plasma from determining a per se charge in ...

Most mutations that decreased antibiotic susceptibility were related to specific metabolic pathways. A MIC-increase to ...

Cells treated with ibrutinib and acalabrutinib each had a unique set of 13 m/z signals, which opens up the possibility of studying these metabolites as biomarkers of therapeutic response.

A new study found chemicals can leach from plastic takeout containers into food, impacting the gut biome—and then the heart ...

A legislative committee in New Mexico has advanced a bill to prohibit employers from considering an employee impaired based ...